Sodium glucose cotransporter 2 inhibitor-induced ketoacidosis is unlikely in patients without diabetes

Med J Aust. 2023 Oct 2;219(7):293-294. doi: 10.5694/mja2.52067. Epub 2023 Aug 7.

Authors

Lisa M Raven^{1

2

3}, Christopher A Muir^{1

3}, Jerry R Greenfield^{1

2

3}

Affiliations

¹ University of New South Wales, Sydney, NSW.
² Garvan Institute of Medical Research, Sydney, NSW.
³ St Vincent's Hospital Sydney, Sydney, NSW.

PMID: 37549922
DOI: 10.5694/mja2.52067

No abstract available

Keywords: Diabetes mellitus, type 2; Kidney diseases; Pharmacovigilance.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Diabetic Ketoacidosis* / chemically induced
Diabetic Ketoacidosis* / diagnosis
Humans
Hypoglycemic Agents / adverse effects
Ketosis* / chemically induced
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents